Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain

ConclusionUp to 82% of patients with atherosclerotic CV disease do not achieve LDL-C levels recommended by the 2019 ESC/EAS guidelines despite being on optimized oral LLT therapy. In 17.9% of these patients LDL-C levels exceed 100 mg/dL, being eligible for PCSK9i in Spain.

http://link.springer.com/10.1007/s12325-022-02384-y

Source: Advances in Therapy - December 16, 2022 Category: Drugs & Pharmacology Source Type: research